Microphthalmia-associated transcription factor is required for mature myotube formation.

Author(s)
Ooishi, Ryo; Shirai, Mitsuyuki; Funaba, Masayuki; Murakami, Masaru

Citation
Biochimica et biophysica acta (2012), 1820(2): 76-83

Issue Date
2012-02

URL
http://hdl.handle.net/2433/153284

© 2011 Elsevier B.V.; This is not the published version. Please cite only the published version. この論文は出版社版ではありません。引用の際には出版社版をご確認ご利用ください。
Microphthalmia-associated transcription factor is required for mature myotube formation

Ryo Ooishi¹, Mitsuyuki Shirai², Masayuki Funaba³,* and Masaru Murakami¹,*

¹Laboratory of Molecular Biology, Azabu University School of Veterinary Medicine, Sagamihara 229-5201, Japan
²Laboratory of Veterinary Pharmacology, Azabu University School of Veterinary Medicine, Sagamihara 229-5201, Japan
³Division of Applied Biosciences, Kyoto University Graduate School of Agriculture, Kyoto 606-8502, Japan

Running title: Role of Mitf in myogenesis

*Correspondence:
Masayuki Funaba, Division of Applied Biosciences, Kyoto University Graduate School of Agriculture (mfunaba@kais.kyoto-u.ac.jp) or Masaru Murakami, Laboratory of Molecular Biology, Azabu University School of Veterinary Medicine (murakami@azabu-u.ac.jp)
Abstract

Background: The roles of microphthalmia-associated transcription factor (Mitf) in the skeletal muscle and during myogenesis are unclear.

Methods: Expression of Mitf in mouse tissues and during myogenesis was evaluated. Effects of Mitf knockdown on myogenesis and gene expression related to myogenesis were subsequently explored. Furthermore, effects of p21, a cyclin-dependent kinase inhibitor, and integrin α9 (Itga9) were examined.

Results: Mitf was highly expressed in the skeletal muscle; Mitf-A and -J were expressed. Mitf expression increased after differentiation stimulation in C2C12 myogenic cells. Down-regulation of Mitf expression by transfection of siRNA for common Mitf inhibited myotube formation, which was reproduced by Mitf-A knockdown. Morphometric analyses indicated that both multinucleated cell number and the proportion of myotubes with more than 6 nuclei were decreased in Mitf-knockdown cells, suggesting that Mitf is required for not only the formation of nascent myotubes but also their maturation. Searching for genes positively regulated by Mitf revealed p21 and Itga9; decreasing Mitf expression inhibited up-regulation of p21 expression after differentiation stimulation and blocked the induction of Itga9 expression in response to differentiation. Knockdown of p21 decreased the number of multinucleated cells, whereas Itga9 knockdown did not affect the myotube number. Both p21 knockdown and Itga9 knockdown decreased the proportion of myotubes with more than 6 nuclei.

Conclusion: The present study clarified that Mitf is significantly expressed during myogenesis, and that Mitf is required for efficient myotube formation through expression of p21 and Itga9.

General significance: Mitf positively regulates skeletal muscle formation.

Keywords: Mitf, myogenesis, integrin, p21, myotube
Introduction

Skeletal muscle formation consists of a complex set of differentiation steps: commitment of mesenchymal stem cells to myoblast lineage cells, progression of differentiation with the expression of muscle-cell-specific proteins, and fusion of myoblasts into multinucleated myotubes. Mammalian myotube formation occurs in two phases [1, 2]. In the first phase, differentiated myoblasts fuse together to form small myotubes; to accomplish this process, proliferating myoblasts exit cell cycle, and some myoblasts undergo apoptosis. In the second phase, additional myoblasts subsequently fuse with myotubes to form large myotubes. Although the roles of myogenic regulatory factors (MRFs), including Myf5, Myod, Myogenin and Mrf4, in myogenic differentiation are unquestionable [3-5], a number of factors, such as secreted proteins, membrane proteins and transcriptional regulators, are also involved in myogenesis [2].

Microphthalmia-associated transcription factor (Mitf) is a member of the basic helix-loop-helix leucine zipper (bHLH-LZ) family of transcription factors [6-8]. Expression levels of Mitf, evaluated by Western blotting and Northern blotting, vary among tissues; it is highly expressed in melanocytes, mast cells, osteoclasts, and the heart [9-11]. Thus, the roles of Mitf have been mainly examined in these cells [11-14], and Mitf activities in other tissues are largely unknown. Of the Mitf variants that are not the result of genetic mutation, nine Mitf isoforms have been identified in mice that differ in their transcriptional initiation site: Mitf-A, -B, -C, -D, -E, -H, -J, -M and -mc. The Mitf variants contain an isoform-specific first exon, while exons 2 to 9 of all Mitf isoforms examined to date are identical. Mitf isoforms are expressed in a cell type-specific manner, and their transcriptional activities are slightly but significantly different depending on the target gene [15-19]. In addition, two types of Mitf mRNAs with or without an 18-base insert (exon 6a) are generated by alternative use of the two acceptor sites located at the 5’ end of exon 6 in Mitf-A, -H, -J, -M and -mc [6, 9, 20, 21]. In the
present study, we show the relatively higher expression of Mitf-A in the skeletal muscle, and present the potential role of Mitf in the progression of myogenesis.

Materials and methods

Animals and cell culture

Nine C57BL/6 mice aged 7-8 wk were used to examine the tissue distribution of Mitf. The experiment was approved by Azabu University Animal Experiment Committee. C2C12 myoblasts were obtained from the American Type Culture Collection (Rockville, MD). Cells were cultured in growth medium, i.e., Dulbecco’s modified Eagle’s medium (DMEM) with heat-inactivated 10% fetal bovine serum (FBS), 100 U/ml penicillin and 100 μg/ml streptomycin, at 37°C under a humidified 5% CO₂ atmosphere. To induce differentiation from myoblasts to myotubes, the medium was replaced at confluence (day 0) with differentiation medium consisting of DMEM with 2% horse serum supplementing the antibiotics. To isolate myotubes, cells on day 7 were trypsinized for a short time under a microscope until detachment of multinucleated cells (~2 min), followed by centrifugation to obtain a myotube-rich fraction.

RT-PCR, restriction fragment length polymorphism and quantitative RT-PCR

Total RNA isolation from tissues and cells, RT-PCR and restriction fragment length polymorphism (RFLP) were performed as described previously [21]. Quantitative RT-PCR (qRT-PCR) was carried out as described previously [22]. The used PCR primers in qRT-PCR are presented in Table 1. To compare tissue Mitf expression, the appropriate corrected gene was chosen using a mouse housekeeping gene primer set (TaKaRa, Otsu, Japan). The relative mRNA level was expressed as a ratio with β-actin to evaluate tissue distribution and Gapdh was used as a reference gene to examine regulatory expression in C2C12 cells.
Western blotting

To examine expression of Mitf in the skeletal muscle, thigh muscle and heart as a positive control were homogenized in RIPA buffer. After 30 min on ice, the debris was removed by centrifugation at 2,500 × g for 2 min at 4°C. After centrifugation at 12,000 × g for 5 min at 4°C, the supernatant was recovered and the protein concentration was measured by the bicinchoninic acid method [23]. Fifty µg of the protein was loaded on 10% SDS-polyacrylamide gel. Western blotting was performed as described previously [24, 25]. Expression of Mitf and myosin heavy chain (Myhc) was examined by use of mouse monoclonal antibodies against Mitf (X1405M; Exalpha Biologicals) and Myhc (MY-32; Sigma), respectively. There are two types of muscle fiber, i.e., fast-twitch and slow-twitch; fast-twitch muscle fibers express Myhc2a, Myhc2b and Myhc2x, whereas slow-twitch muscle fibers do Myhc1 [26]. According to the manufacturer’s manual, this antibody for Myhc recognizes fast-type muscle fibers. After incubation of the membranes with ECL Advance reagent (GE Healthcare), the chemiluminescent signals were exposed to X-ray film. Subsequently, antibodies as well as the detection reagents were stripped and reprobed with anti-α-tubulin (ab11304; Abcam) or anti-β-actin antibody (AC-15; Abcam).

Immunohistochemistry

C2C12 cells were grown on glass chamber slides coated with type I collagen (Thermo Fisher Scientific) and were fixed with 3% paraformaldehyde in PBS for 30 min, followed by treatment with 1% Triton X-100 in PBS for 10 min. After washing with PBS, cells were incubated with 3% H2O2 to remove endogenous peroxidase. Subsequently, cells were treated with 1.5% normal goat serum in PBS for 20 min to block nonspecific reactions. Diluted mouse monoclonal antibody against Mitf (X1405M; Exalpha Biologicals) with 0.1% bovine serum albumin in PBS at 1 : 80 was
used to identify Mitf expression at the protein level. After incubation with the primary antibody for 2 h at room temperature, Mitf-positive cells were visualized using VECTASTAIN Elite ABC kit (Vector Laboratories) and 3,3’-diaminobenzidine (DAB; Dojindo) according to the manufacturer’s protocol.

**siRNA transfection**

To target the expression of common *Mitf, Mitf-A* or *Itga9* and green fluorescent protein (*GFP*) controls, oligonucleotides for the respective genes were synthesized by BONAC corporation (Kurume, Japan) as follows: 5’-GAAACUUGAUCGACCUCUACA-3’ and 5’-UAGAGGGUCGAUCAAGGUUCCA-3’ for common *Mitf*, 5’-GGAGUCAUGCAGUCCGAUTT-3’ and 5’-AUUCGGACUGCAUGACUCCTT-3’ for *Mitf-A*, 5’-CCUUAGUGCUCUUCCGAAAGA-3’ and 5’-UUUCGGAAGACACUAAGGUU-3’ for *Itga9*, and 5’-GGUUACGUCCAGGAGCGCATT-3’ and 5’-UGCGCUCCUUGGACGUAGCCTT-3’ for *GFP*. The siRNA for *p21* was purchased (sc-29428; Santa Cruz Biotechnology). An equal amount of the oligonucleotide was mixed for each gene to prepare siRNA. Thirty picomoles of siRNA was transfected into C2C12 cells seeded at a density of $1.5 \times 10^4$ cells in 24-well plates every 48 h. siRNA was transfected using Lipofectamine RNAiMAX (Invitrogen) according to the manufacturer’s protocol. Antibiotics were not supplemented to the culture media in siRNA transfection experiments.

**Morphological analysis**

Cells were fixed with methanol for 2 min and subsequently stained with Giemsa staining for 20 min. Cells with more than 3 nuclei were judged as myotubes. Eight views per treatment in an experiment were analyzed. Experiments were repeated two or three times, and similar results were obtained.
BrdU incorporation

Proliferation of C2C12 cells was measured by a BrdU cell proliferation assay (Cell Proliferation ELISA, BrdU (colorimetric); Roche) according to the manufacturer’s protocol.

Statistical analysis

Data are presented as the mean ± SE. Comparisons between groups were conducted using Student’s t-test. Results were considered significant at \( P < 0.05 \).

Results

Expression of Mitf in tissues and during myogenesis

Tissue distribution of Mitf was quantified by qRT-PCR. First, the expressions of 12 genes, Atp5f1, B2m, \( \beta \)-actin, Gapdh, Hprt1, Pgk1, Ppia, RpLp1, Rps18, Tbp, Tfrc, and Ywhaz, were quantified for evaluation as appropriate corrected genes; quantitative PCR using cDNA prepared from equal amounts of total RNA revealed that \( \beta \)-actin expression was the most stable among the tested tissues, which were evaluated by “geNorm” (http://medgen.ugent.be/~jvdesomp/genorm/) (data not shown). Thus, the gene transcript level of Mitf was corrected for that of \( \beta \)-actin (Fig. 1A). Expression of Mitf was highest in the heart, as expected. Although Mitf is recognized as a tissue-restricted transcription factor [6-8], its expression was detected in a wide variety of tissues. In particular, expression in the skeletal muscle was relatively higher. Previous studies indicated Mitf expression in the skeletal muscle [9, 27], but the role of Mitf is not known. Thus, we characterized the expression and function of Mitf in the skeletal muscle and during myogenesis in detail. Examining Mitf isoforms differing in transcriptional initiation site in the skeletal muscle indicated that more than 99% of Mitf
was Mitf-A, and that Mitf-H and -J were also expressed significantly (Fig. 1B).

In a C2C12 myotube differentiation model, C2C12 myoblasts fuse to form multinucleated myotube cells upon serum starvation on day 0 [28]. To evaluate gene expression in C2C12 cells, we chose Gapdh instead of β-actin as a reference gene; qPCR using cDNA prepared from equal amount of total RNA indicated gradual decrease in β-actin expression with progression of myogenesis, whereas expression of Gapdh was relatively constant (Supplementary Fig. 1). Total Mitf expression level increased up to day 8 and then reached a plateau (Fig. 1C). Similar to the expression pattern in the skeletal muscle, Mitf-A was the main isoform (59-76% of total Mitf). In addition, Mitf-J but not -H was expressed. The expression pattern of Mitf isoform was constant during myogenesis; the ratio of Mitf-A to Mitf-J was 1.5 to 3.2 : 1. Expression of Mitf in the skeletal muscle and C2C12 cells was also verified at the protein level by Western blot analyses (Fig. 1D). In addition, consistent with the changes at the mRNA level, expression of Mitf protein was increased after differentiation stimulation (Fig. 1E). Furthermore, Mitf was exclusively localized in the nucleus of C2C12 cells (Fig. 1F).

Disruption of Mitf expression inhibits myotube formation by blocking increased expression of p21 and Itga9 induction

To clarify the roles of Mitf in myogenesis, we evaluated effects of decreased expression of Mitf, which was achieved by transfection with siRNA for Mitf (Supplementary Fig. 2A, lanes 2 and 3, and B). Transfection of siRNA for common Mitf effectively decreased the emergence of multinucleated myotubes on day 6, as compared with GFP (Fig. 2A). Knockdown of Mitf-A also blocked the formation of thick myotubes (Fig. 2B,
Supplementary Fig. 2C). Morphological analyses on day 6 indicated that the number of multinucleated cells, which were defined as cells with more than 3 nuclei, was significantly decreased by transfection of siRNA for Mitf (Fig. 2C). We also evaluated the differentiated myotubes in detail; knockdown of Mitf increased the proportion of myotubes with 3 to 5 nuclei, but decreased that of myotubes with more than 6 nuclei (Fig. 2D). Similar results were also obtained in C2C12 cells transfected with siRNA for Mitf-A (Supplementary Fig. 3). Furthermore, Mitf knockdown decreased the expression of Myhc, a myotube-specific protein [3-5], in C2C12 cells on day 8 (Fig. 2E, lanes 1 and 2). These results suggest that Mitf is required not only for myoblast-myoblast fusion but also for maturation of nascent myotubes. We also examined effects of forced Mitf expression on myotube formation; the expression did not enhance myogenesis (data not shown).

Molecular bases of decreased myotube formation by Mitf knockdown were then explored. Myogenesis is regulated through modulation of the expression and activity of MRFs [29, 30]; however, gene transcript levels of Myf5, Myod, Myogenin and Mrf4 were unchanged by Mitf knockdown, suggesting that impairment of myogenesis resulting from Mitf knockdown is not due to altered expression of MRFs (Fig. 3A-D).

Other than MRFs, several molecules related to cell attachment and fusion, such as Adam12, Calpastatin, Caveolin3, Cdh15, Ctsb, Itga3, Itga4, Itga6, Itga9, Itgb1, Myof, and v-Caml are known to regulate myotube differentiation [2, 31-34]. In addition, the cDNA microarray database (http://www.ncbi.nlm.nih.gov/geo/) indicated that the expressions of Ccna2, Itga5, p21, p57, Ptger4, Rb1, and Vcl increased with differentiation. In view of Mitf as a transcription factor, we expected that Mitf is involved in myogenesis through transcriptional activation of these myogenesis-regulating genes. Thus, the effects of decrease in Mitf expression on the
expression level of these genes were explored. We found that gene transcript levels of p21 and Itga9 after differentiation stimulation were decreased by transfection of siRNA for common Mitf; expression of p21 was increased in response to differentiation stimulation, and Mitf knockdown blocked the increased expression of p21 (Fig. 3E). Significant expression of Itga9 was detected after day 4, and the expression level was decreased by transfection of siRNA for Mitf (Fig. 3F). Decreased expression of p21 and Itga9 was also detected in Mitf-A-knockdown cells (Supplementary Fig. 4). Gene transcript levels of the other genes were unaffected by Mitf knockdown (Supplementary Fig. 5).

In a C2C12 myogenesis cell model, not all myoblasts not fuse into myotubes; co-existence of proliferating myoblasts and myotubes is detected after differentiation stimulation [35-37]. We separated the myotube-rich fraction by limited trypsinization to explore cells affected by Mitf knockdown. Although Myhc2a expression was not significantly different between the myotube fraction and the residual cell fraction in control cells (Fig. 4A), Myhc2b and Myhc2x were predominantly expressed in the myotube fraction as expected (Fig. 4B and C). Expression of Myhc2x in the myotube fraction was significantly lower in Mitf-knockdown cells than in control cells, whereas that of Myhc2a in the myotube fraction was higher in the Mitf-knockdown cells. The Myhc2b expression in the myotube fraction was comparable between in control cells and in Mitf-knockdown cells. Considering that Myhc2x was the major isoform of type 2 Myhc (> 93%) (Fig. 4D), total expression of Myhc constituting of fast-twitch myofibers was largely limited to the myotube fraction, and was decreased by Mitf knockdown; the latter was consistent with the results on Myhc expression at the protein level (Fig. 2E).

The extent of the decreased expression of Mitf resulting from knockdown of Mitf was comparable between the myotube fraction and the residual cell fraction, indicating
effective inhibition of Mitf expression in both myoblasts and myotubes (Fig. 5A). Expression of p21 was significantly higher in the myotube fraction than in the residual cell fraction (Fig. 5B). Knockdown of Mitf equally decreased the expression of between the two fractions. Expression of Itga9 was also significantly higher in the myotube fraction (Fig. 5C). Similar to the expression of p21, Mitf knockdown down-regulated the expression of Itga9 in both fractions.

Cell cycle exit in response to differentiation stimulation is a prerequisite for myotube formation [2]; p21, a cyclin-dependent kinase inhibitor inducing cell cycle exit, plays a role in post-mitotic myogenesis, although it also maintains anti-apoptotic states in differentiated myocytes [1]. To link the decreased Mitf-induced inhibition of myotube formation and blockage of p21 induction, effects of the decreased Mitf expression on BrdU uptake were next examined; BrdU uptake was significantly increased by transfection of siRNA for Mitf on day 4-6 (Fig. 5A). Knockdown of p21, however, did not affect BrdU uptake (Fig. 5B). Similar to Mitf knockdown, decreased expression of p21 inhibited emergence of maturated and thick myotubes (Fig. 5C). In addition, it significantly decreased the number of multinucleated cells (Fig. 5D), and increased and decreased the proportion of myotubes with 3 to 5 nuclei and those with more than 6 nuclei, respectively (Fig. 5E).

We next explored the effects of Itga9 knockdown on myotube formation. The morphology of cells transfected with siRNA for Itga9 indicated that, compared to control cells, thinner myotubes were evident by Itga9 knockdown, suggesting that Itga9 is required for myotube maturation (Fig. 6A), which was verified by morphometry. The multinucleated cell number itself was not affected by knockdown of Itga9 (Fig. 6B), but the proportion of the number of myotubes with 3-5 nuclei in a cell to that of total myotubes was significantly increased, and that with more than 6 nuclei was decreased
(Fig. 6C). Consistent with the results, knockdown of Itga9 gene resulted in the decreased expression of Myhc (Fig. 2E, lanes 1 and 3).

Discussion
Here, we demonstrate that 1) A isoform of Mitf mRNA is abundant in the skeletal muscle, 2) Mitf-A expression increased with progression of myogenesis, 3) knockdown of Mitf mRNA disrupts myotube formation through inhibition of myoblast-myoblast fusion and subsequent myoblast-myotube fusion, but does not affect the expression of MRFs, and 4) expression of p21, a cyclin-dependent kinase inhibitor, and Itga9 is regulated by Mitf in a stage-dependent manner for appropriate myogenesis. The present results indicate a novel role of a tissue-restricted transcription factor Mitf in the regulation of myogenesis, which is probably mediated by an MRF-independent pathway.

Mitf regulates myogenesis in multiple steps. Expression of p21 and Itga9 was modulated by decreased expression of Mitf; down-regulation of p21 expression resulting from knockdown of Mitf mRNA was limited to post-differentiation, and significant Itga9 expression was detected just after differentiation stimulation. Considering that significant expression of Mitf was detected prior to differentiation stimulation, the gene expression of p21 and Itga9 could not be regulated by Mitf alone, but in concert with Mitf and as yet unidentified factor(s). Transfection of siRNA for Mitf resulted in down-regulated expression of Mitf both in myoblasts and myotubes. Thus, the precise mechanism of how Mitf regulates not only p21 in myoblasts and myotubes but also Itga9 expression in myotubes remains unclear. Since Mitf binds to the E-box (CAAnTG) located in the 5'-untranslated region and activates transcription [6-8], Mitf may directly regulate transcription of p21 and Itga9. Alternatively, it is possible that a factor
regulated by Mitf in myoblasts acts as a regulator to induce p21 or Itga9 in myotubes.

A target gene of Mitf was Itga9. Among members of the integrin family, Itga3, 4, 6 and 9 have been suggested to regulate myogenesis [2, 31, 33, 34]. Transcription of Itga4 was activated through Mitf binding to the E-box located in the 5'-untranslated region in mast cells [38]. In the present study, however, Itga4 mRNA was not decreased but rather increased by transfection of siRNA for Mitf in C2C12 cells (Supplementary Fig. 2H), suggesting that transcription by Mitf is regulated in a cell context-dependent manner. In addition, Mitf knockdown did not affect the expression level of Itga3 and 6 (Supplementary Fig. 2G and J). In a study using a human mononucleated myogenic precursor cell culture system, addition of anti-INTEGRIN α9β1 antibody to the culture medium decreased the proportion of nuclei included in large myotubes (≥5 nuclei), whereas the proportion of nuclei incorporated in small myotubes (2-4 nuclei) was unchanged [33]. In the present study using a murine myogenesis model, transfection with siRNA for Itga9 decreased the proportion of large myotubes (≥6 nuclei) and increased that of small myotubes (3-5 nuclei), but did not affect the number of multinucleated cells. Taking these results together, Itga9 is suggested to promote the growth of preformed myotubes rather than the formation of nascent myotubes during myogenesis.

Effects of knockdown of Mitf mRNA partly overlapped but were distinct from those of Itga9 knockdown; the number of multinucleated cells was decreased by Mitf knockdown. This suggests that Mitf is involved in both myoblast-myoblast fusion and subsequent maturation of nascent myotubes. It is possible that Mitf regulates myoblast-myoblast fusion through the increase in p21 expression; regulatory expression of p21 by Mitf has also been shown in melanocytes [39]. Cell cycle inhibition and apoptosis of myoblasts precede to myoblast-myoblast fusion, and both processes are
necessary for the cell fusion [1]. p21 is principally involved as a molecule to establish post-mitotic and apoptosis-resistant states [1]; BrdU uptake was not detected in p21-positive myoblasts [40], and forced expression of p21 but not inactive p21 inhibited apoptosis of C2C12 myoblasts [41]. In fact, p21 knockdown decreased the myotube number and increased proportion of small myotubes, suggesting that p21 expression is required for efficient myoblast-myoblast fusion.

Knockdown of p21 did not increase BrdU uptake on day 4 and 6; it may be offset effects of the cell growth inhibition and the anti-apoptotic activity. In view of significant inhibition of BrdU uptake in Mitf-knockdown cells on day 4 and 6, Mitf regulates expression and activity of additional molecule(s) unidentified in this study.

Bharti et al. [19] revealed that Mitf-A and -J are expressed throughout eye development in both retina and pigment epithelium, whereas expression of Mitf-D and -M was limited to pigment epithelium. In addition, Mitf-H was preferentially found in pigment epithelium with temporal expression profile. Unlike the eye development, the proportion of expressed Mitf isoforms, i.e., Mitf-A and Mitf-J was almost constant during myogenesis of C2C12 cells, although total Mitf expression was increased with progression of myogenesis (Fig. 1C). Thus, expression of Mitf isoforms is tissue-specific and stage-dependent. In view of different activity as transcription factors between the isoforms [15-18], regulation on the use of alternative promoter must be clarified in future studies.

Mitf encoded by the mutant mi allele deletes one of four consecutive arginines in the basic domain, and acts as a dominant-negative mutant [9, 27, 42]. The mi/mi mutant mice exhibited the pleiotropic effects of microphthalmia, depletion of pigment in both hair and eyes, and osteopetrosis resulting from defects of osteoclastogenesis [9, 14]. In
addition to these phenotype alterations, Katayama et al. [43] recently showed that
masseter muscle development was disrupted in mi/mi mutant mice; they speculated that
the disorder is a secondary event related to abnormal tooth formation related to
osteoclast dysfunction; however, in view of the present results showing direct inhibition
of myogenesis by decreased expression of Mitf, muscle development itself may be
disturbed in mi/mi mice.

The present study indicates significant expression of Mitf in the skeletal muscle from
re-evaluation of tissue distribution of Mitf by sensitive qRT-PCR analyses. Evaluation
of Mitf activity clarifies its role as a positive regulator during myogenesis. Because Mitf
is expressed also in other tissues with a variation of expression level, future studies
should be directed to elucidate the role of Mitf in as yet uncharacterized tissues.

Acknowledgements

This work was supported by Kakenhi from The Japan Society for the Promotion of
Science, and a research project grant awarded by the Azabu University.

References


Figure legends

Fig. 1. Mitf expression is highly expressed in the skeletal muscle and increases with progression of myogenesis in C2C12 cells

(A) Mitf expression in various tissues was measured by qRT-PCR. Mitf expression was expressed as a ratio to β-actin expression. Data are shown as the mean ± SE. (B) Expression of Mitf isoform differing with transcriptional initiation site in the skeletal muscle was identified by qRT-PCR using isoform-specific 5’-primer and 3’-primer spanning the common Mitf. The percentage of the expression of each Mitf isoform to that of total Mitf was calculated. Data are shown as the mean ± SE. (C) C2C12 myoblasts were cultured to confluence (day 0) in growth medium, followed by culture in differentiation medium. Time-course changes in expression of Mitf isoform differing with transcriptional initiation site during myogenesis were examined in C2C12 cells. Mitf expression was expressed as a ratio to Gapdh expression. Data are shown as the mean ± SE (n = 2). (D) Expression of Mitf in the skeletal muscle. Protein extracted from heart, thigh muscle and C2C12 cells was subjected to Western blot analyses to examine Mitf expression at the protein level. A representative result of Western blot is shown. In the heart, Mitf-H as well as Mitf-A is mainly expressed shown in (B). Note that calculated molecular weight of Mitf-H and Mitf-A is 56.8 k and 58.6 k, respectively. (E) Time-course changes in expression of Mitf protein were examined during myogenesis of C2C12 cells. A representative result of Western blot is shown. (F) Immunolocalization of Mitf in C2C12 cells. C2C12 myoblasts were fixed and reacted with (right) or without (left) mouse monoclonal anti-Mitf antibody. Subsequently, cells were reacted with anti-mouse IgG antibody, and the antibody was visualized. A representative cell staining is shown. (G) The ratio of exon 6a-containing Mitf isoforms (exon 6a + 6b) to non-exon 6a-containing isoforms (exon 6b) was evaluated in C2C12 cells. PCR products of Mitf-A and -J were digested by Hinf I, and DNA fragments with or without exon 6a were separated by PAGE. A photograph of a representative gel
stained with ethidium bromide is shown.

Fig. 2. Mitf expression is required for efficient myotube formation
C2C12 cells were transfected with siRNA for GFP as a control, common Mitf or Mitf-A every 2 days after day -2. (A) Effect of Mitf knockdown on myogenensis was evaluated. Representative phase-contrast images on day 0, 2, 4, and 6 are presented. (B) Role of Mitf-A was examined. Representative cells stained by Giemsa solution on day 6 are presented. (C and D) Myotube formation was evaluated in Mitf-knockdown C2C12 cells. Cells were transfected with siRNA for GFP as a control or Mitf, and morphology was evaluated on day 6. After staining with Giemsa solution, cell number and the number of nuclei were calculated. (C) Ratio of multinucleated cell number to total cell number was calculated, and the ratio of cells transfected with siRNA for GFP was set to 1. (D) Number of cells with 3 to 5, 6 to 10 or >11 nuclei were counted, and percentage to total multinucleated cells is shown. Data are shown as the mean ± SE (n = 6). * and **: P < 0.05 and P <0.01, respectively, as compared to control. (E) Expression of Myhc in response to transfection of siRNA for GFP as a control, Mitf or Itga9 in C2C12 cells on day 8 was examined by Western blot analyses. Subsequently, the membranes were reprobed with anti-β-actin antibody.

Fig. 3. p21 and Itga9 are targets of Mitf for progression of myogenensis
C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 days after day -2. Gene expression of Myf5 (A), Myod (B), Myogenin (C), Mrf4 (D), p21 (E) and Itga9 (F) was quantified by qRT-PCR. The expression was normalized to Gapdh expression. The expression in cells on day -2 was set to 1 for Myf5, Myod, Myogenin, Mrf4 and p21, and that in cells transfected with siRNA for GFP on day 4 was set to 1 for Itga9. Data are shown as the mean ± SE (n = 2).
Fig. 4. Knockdown of Mitf in myoblasts and myotubes down-regulates expression of Myhc2x

C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 days after day -2. On day 7, multinucleated myotubes were separated from the residual cells by limited trypsinization. Expression of Myhc2a (A), Myhc2b (B) and Myhc2x (C) was quantified by qRT-PCR, and normalized to Gapdh expression. The expression in residual cells after limited trypsinization in the control group was set to 1. (D) The percentage of the expression of each Myhc isoform to that of total type II Myhc was calculated. Data are shown as the mean ± SE (n = 3). a, b, c, d: Means that do not have a common letter on the bar differ significantly (P < 0.05).

Fig. 5. Knockdown of Mitf in myoblasts and myotubes down-regulates expression of p21 and Itga9

C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 days after day -2. On day 7, multinucleated myotubes were separated from the residual cells by limited trypsinization. Expression of Mitf (A), p21 (B), and Itga9 (C) was quantified by qRT-PCR, and normalized to Gapdh expression. The expression in residual cells after limited trypsinization in the control group was set to 1. Data are shown as the mean ± SE (n = 3). a, b, c, d: Means that do not have a common letter on the bar differ significantly (P < 0.05).

Fig. 6. p21 is involved in Mitf-mediated myogenesis

(A and B) Role of Mitf and p21 in BrdU uptake in C2C12 cells was evaluated. (A) Cells were transfected with siRNA for GFP as a control or common Mitf every 2 days after day -2, and BrdU uptake was examined on day -1, 0, 4 and 6. BrdU uptake in control cells on day -1 was set to 100. (B) Cells were transfected with siRNA for GFP or p21 every 2 days after day 2, and BrdU uptake was examined on day 4 and 6. Data are
shown as the mean ± SE (n = 3-4). **: P < 0.01, as compared to control. (C-E) Role of p21 in myogenesis was evaluated. Cells were transfected with siRNA for GFP or p21 every 2 days after day 2. (C) Representative cells stained by Giemsa solution on day 6 are shown. (D and E) Myotube formation was evaluated in p21-knockdown C2C12 cells. After staining cells with Giemsa solution on day 6, cell number and the number of nuclei were calculated. (D) Ratio of multinucleated cell number to total cell number was calculated, and the ratio of cells transfected with siRNA for GFP was set to 1. (E) Number of cells with 3 to 5, 6 to 10 or >11 nuclei was counted, and percentage to total multinucleated cells is shown. Data are shown as the mean ± SE (n = 4). * and **: P < 0.05 and P < 0.01, respectively, as compared to control.

Fig. 7. Itga9 are involved in Mitf-mediated myogenesis

(A-C) Role of Itga9 in myogenesis was evaluated. Cells were transfected with siRNA for GFP or Itga9 every 2 days after day -2. (A) Representative cells stained by Giemsa solution on day 6 are shown. (B and C) Myotube formation was evaluated in Itga9-knockdown C2C12 cells. After staining cells with Giemsa solution on day 6, cell number and the number of nuclei were calculated. (B) Ratio of multinucleated cell number to total cell number was calculated, and the ratio of cells transfected with siRNA for GFP was set to 1. (C) Number of cells with 3 to 5, 6 to 10 or >11 nuclei was counted, and percentage to total multinucleated cells is shown. Data are shown as the mean ± SE (n = 4). **: P < 0.01, as compared to control.

Supplementary Fig. 1 Time-course changes in expression of Gapdh and β-actin during myogenesis of C2C12 cells

C2C12 myoblasts were cultured to reach confluence (day 0) in growth medium, followed by culture in differentiation medium. Expression of Gapdh and β-actin using
cDNA prepared from 5 ng of total RNA was quantified by qRT-PCR, and normalized to Hprt1 expression. The expression on day 0 was set to 1. Data are shown as the mean ± SE (n = 2).

Supplementary Fig. 2 Effects of Mitf knockdown on Mitf expression in C2C12 cells
(A) C2C12 cells were transfected with siRNA for GFP as a control (c, lane 2) or common Mitf (M, lane 3) for 2 days. Western blot analyses were performed to examine Mitf expression. As a positive control, lysates of B16 melanoma cells were used (lane 1). B16 cells express mainly Mitf-M, whereas C2C12 cells predominantly express Mitf-A as shown in Fig. 1C. Note that calculated molecular weight of Mitf-M (46.8 k) is smaller than that of Mitf-A (58.6 k). (B and C) C2C12 cells were transfected with siRNA for GFP as a control, common Mitf or Mitf-A every 2 days after day -2. Gene expression of common Mitf (B) and Mitf-A (C) was quantified by qRT-PCR. The expression was normalized to Gapdh expression. The expression in cells on day -2 was set to 1. Data are shown as the mean ± SE (n = 2).

Supplementary Fig. 3 Impaired myotube formation in C2C12 cells transfected with siRNA for Mitf-A
C2C12 cells were transfected with siRNA for GFP as a control or Mitf-A every 2 days after day -2. (A and B) Myotube formation was evaluated in Mitf-A-knockdown C2C12 cells. Cells were transfected with siRNA for GFP as a control or Mitf-A, and morphology was evaluated on day 6. After staining with Giemsa solution, cell number and the number of nuclei were calculated. (A) Ratio of multinucleated cell number to total cell number was calculated, and the ratio of cells transfected with siRNA for GFP was set to 1. (B) Number of cells with 3 to 5, 6 to 10 or >11 nuclei were counted, and percentage to total multinucleated cells is shown. Data are shown as the mean ± SE (n =
6). * and **: \( P < 0.05 \) and \( P <0.01 \), respectively, as compared to control.

Supplementary Fig. 4 Decreased expression of p21 and Itga9 in C2C12 cells transfected with siRNA for Mitf-A

C2C12 cells were transfected with siRNA for GFP as a control or Mitf-A every 2 days after day -2. Gene expression of p21 (A) and Itga9 (B) was quantified by qRT-PCR. The expression was normalized to Gapdh expression. The expression in cells transfected with siRNA for GFP on day -2 was set to 1. Data are shown as the mean ± SE (n = 2).

Supplementary Fig. 5 Effects of Mitf knockdown on gene expression in C2C12 cells

C2C12 cells were transfected with siRNA for GFP as a control or common Mitf every 2 days after day -2. Gene expression of Adam12 (A), Calpastatin (B), Caveolin3 (C), Ccna2 (D), Cdh15 (E), Ctsb (F), Itga3 (G), Itga4 (H), Itga5 (I), Itga6 (J), Itgb1 (K), Myof (L), p57 (M), Ptger4 (N), Rb1 (O), v-Cam1 (P), and Vcl (Q) was quantified by qRT-PCR. The expression was normalized to Gapdh expression. The expression in cells on day -2 was set to 1. Data are shown as the mean ± SE (n = 2).
Figure 1F, G (Ooishi)

**Figure 1F**

- Prim. Ab

**Figure 1G**

<table>
<thead>
<tr>
<th>Day</th>
<th>RT-PCR</th>
<th>RFLP</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.30</td>
<td>1.20</td>
</tr>
<tr>
<td>2</td>
<td>1.22</td>
<td>1.20</td>
</tr>
<tr>
<td>4</td>
<td>1.38</td>
<td>1.38</td>
</tr>
<tr>
<td>6</td>
<td>1.29</td>
<td>1.29</td>
</tr>
<tr>
<td>8</td>
<td>1.33</td>
<td>1.33</td>
</tr>
<tr>
<td>10</td>
<td>1.29</td>
<td>1.29</td>
</tr>
<tr>
<td>12</td>
<td>1.40</td>
<td>1.40</td>
</tr>
<tr>
<td>14</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Mitf-A**

- (6a+6b):(6b)

**Mitf-J**

- (6a+6b):(6b)

Prim. Ab
Figure 2 (Ooishi)

A

Day:

control 0 2 4 6
si-Mitf 0 2 4 6

B

control si-Mitf si-Mitf-A

C

relative number of multinucleated cell

control
si-Mitf

D

relative number of multinucleated cell

control
si-Mitf

E

Myhc

relative number of multinucleated cell

3-5 6-10 11<

control
si-Mitf
si-Itga9

β-actin

1 2 3
Figure 3 (Ooishi)

A. Myf5

<table>
<thead>
<tr>
<th>Day</th>
<th>Control</th>
<th>si-Mitf</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

B. Myod

<table>
<thead>
<tr>
<th>Day</th>
<th>Control</th>
<th>si-Mitf</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

C. Myogenin

<table>
<thead>
<tr>
<th>Day</th>
<th>Control</th>
<th>si-Mitf</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

D. Mrf4

<table>
<thead>
<tr>
<th>Day</th>
<th>Control</th>
<th>si-Mitf</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

E. p21

<table>
<thead>
<tr>
<th>Day</th>
<th>Control</th>
<th>si-Mitf</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>1.0</td>
</tr>
<tr>
<td>2</td>
<td>0.5</td>
<td>1.5</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.0</td>
<td>1.0</td>
</tr>
</tbody>
</table>

F. Itga9

<table>
<thead>
<tr>
<th>Day</th>
<th>Control</th>
<th>si-Mitf</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>1.0</td>
<td>0.5</td>
</tr>
<tr>
<td>2</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>4</td>
<td>0.5</td>
<td>1.0</td>
</tr>
<tr>
<td>6</td>
<td>1.0</td>
<td>0.5</td>
</tr>
</tbody>
</table>
Figure 4 (Ooishi)

A. **Myhc2a**

B. **Myhc2b**

C. **Myhc2x**

D. Relative expression level to total Myhc expression
Figure 6 (Ooishi)

A. BrdU uptake

B. BrdU uptake

C. Control and si-p21 images

D. Relative number of multinucleated cells

E. Relative number of multinucleated cells by nuclear number
Figure 7 (Ooishi)

A

control

si-ltga9

B

relative number of multinucleated cell

control vs si-ltga9

C

relative number of multinucleated cell

nuclear number

control vs si-ltga9

**
Supplementary Figure 1 (Ooishi)

The figure shows the relative mRNA levels of \( \beta \)-actin and Gapdh over 14 days post-differentiation. The y-axis represents the relative mRNA level, ranging from 0.0 to 1.0. The x-axis represents days post-differentiation, with values at 0, 7, and 14.

- \( \beta \)-actin is represented by open circles and a solid line.
- Gapdh is represented by open squares and a dashed line.

The data points are accompanied by error bars, indicating variability or uncertainty in the measurements.
Supplementary Figure 2 (Ooishi)

A

B

C

Day: 0 2 4 6

relative mRNA level

mitf-A

control

si-Mitf-A

Day: 0 2 4 6

relative mRNA level

mitf

control

si-Mitf

Day: 0 2 4 6

relative mRNA level

mitf-mRNA level

Control

si-Mitf

Day: 0 2 4 6

relative mRNA level

mitf

control

si-Mitf

Day: 0 2 4 6

relative mRNA level

mitf-mRNA level

Control

si-Mitf
Supplementary Figure 4 (Ooishi)

A) *p21* mRNA levels over time with control and si-Mitf-A treatments.

B) *Itga9* mRNA levels over time with control and si-Mitf-A treatments.
Supplementary Figure 2M-Q (Ooishi)

M

\( p57 \)

<table>
<thead>
<tr>
<th>Day:</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>0.6</td>
<td>1.0</td>
<td>0.8</td>
<td>0.5</td>
</tr>
<tr>
<td>si-Mitf</td>
<td>0.8</td>
<td>1.2</td>
<td>1.0</td>
<td>0.7</td>
</tr>
</tbody>
</table>

N

\( Ptger4 \)

<table>
<thead>
<tr>
<th>Day:</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>1.0</td>
<td>2.0</td>
<td>1.5</td>
<td>1.0</td>
</tr>
<tr>
<td>si-Mitf</td>
<td>1.2</td>
<td>2.2</td>
<td>1.8</td>
<td>1.5</td>
</tr>
</tbody>
</table>

O

\( Rb1 \)

<table>
<thead>
<tr>
<th>Day:</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>3.0</td>
<td>4.0</td>
<td>3.5</td>
<td>3.0</td>
</tr>
<tr>
<td>si-Mitf</td>
<td>3.2</td>
<td>4.2</td>
<td>3.8</td>
<td>3.3</td>
</tr>
</tbody>
</table>

P

\( v-Cam1 \)

<table>
<thead>
<tr>
<th>Day:</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>4.0</td>
<td>3.0</td>
<td>2.0</td>
<td>1.0</td>
</tr>
<tr>
<td>si-Mitf</td>
<td>4.2</td>
<td>3.2</td>
<td>2.2</td>
<td>1.2</td>
</tr>
</tbody>
</table>

Q

\( Vcl \)

<table>
<thead>
<tr>
<th>Day:</th>
<th>0</th>
<th>2</th>
<th>4</th>
<th>6</th>
</tr>
</thead>
<tbody>
<tr>
<td>control</td>
<td>0.5</td>
<td>1.0</td>
<td>1.5</td>
<td>2.0</td>
</tr>
<tr>
<td>si-Mitf</td>
<td>0.6</td>
<td>1.2</td>
<td>1.6</td>
<td>2.2</td>
</tr>
<tr>
<td>Table 1. Oligonucleotide PCR primers for qRT-PCR</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Oligonucleotide</strong></td>
<td><strong>5’-primer</strong></td>
<td><strong>3’-primer</strong></td>
<td><strong>GenBank accession number</strong></td>
<td></td>
</tr>
<tr>
<td>-----------------------------------------------</td>
<td>---------------------</td>
<td>---------------------</td>
<td>-----------------------------</td>
<td></td>
</tr>
<tr>
<td><strong>Mitf</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Common Mitf</td>
<td>5’-GCCCTTGCAATGGCAAATAC-3’</td>
<td>5’-GCTGGACAGGAGTTGCTGAT-3’</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mitf-A</td>
<td>5’-GAGGAGTTTCACGAGAGACC-3’</td>
<td>5’-GCTGGCCTAGCAAGATGCTGTA-3’</td>
<td>NM_001113198</td>
<td></td>
</tr>
<tr>
<td>Mitf-H</td>
<td>5’-GAGGAGTTTCACGAGAGACC-3’</td>
<td>5’-GCTGGCCTAGCAAGATGCTGTA-3’</td>
<td>NM_001178049</td>
<td></td>
</tr>
<tr>
<td>Mitf-J</td>
<td>5’-CCGTGTCTCTGCGACATCTGAG-3’</td>
<td>5’-GCTGGCCTAGCAAGATGCTGTA-3’</td>
<td>NY632575</td>
<td></td>
</tr>
<tr>
<td>Mitf-M</td>
<td>5’-ATGCTGGAAATGCTAGATAACAG-3’</td>
<td>5’-GCTGGCCTAGCAAGATGCTGTA-3’</td>
<td>NM_008601</td>
<td></td>
</tr>
<tr>
<td>Myogenic regulatory factors:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myf5</td>
<td>5’-GCCAGTTTCCTCCCTCTTGAGTA-3’</td>
<td>5’-TGGGCCCTAACACTCATCCTAC-3’</td>
<td>NM_008656</td>
<td></td>
</tr>
<tr>
<td>Myod1</td>
<td>5’-GTCGAGCGCGAGACTA-3’</td>
<td>5’-GGGCCGCTGTAATCCATC-3’</td>
<td>NM_010866</td>
<td></td>
</tr>
<tr>
<td>Myogenin</td>
<td>5’-AGAAGCGAGGCTCAAGAAA-3’</td>
<td>5’-ATCTCCACTTTAGGAGCGCC-3’</td>
<td>NM_031189</td>
<td></td>
</tr>
<tr>
<td>Mrf4</td>
<td>5’-GGGCCTCGTGATAAATGCT-3’</td>
<td>5’-AAGAAGGCGCTGAAACTC-3’</td>
<td>NM_008657</td>
<td></td>
</tr>
<tr>
<td>Myosin heavy chains:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myh2a</td>
<td>5’-AAAGCTCCAAGGACCCCTCTT-3’</td>
<td>5’-AGCTCATGACTGCTGAGACAC-3’</td>
<td>NM_001039545</td>
<td></td>
</tr>
<tr>
<td>Myh2b</td>
<td>5’-CCGAGCAAGAGCTAGCAGA-3’</td>
<td>5’-TGTGGATGAGCGTTGTGTCAC-3’</td>
<td>NM_010855</td>
<td></td>
</tr>
<tr>
<td>Myh2x</td>
<td>5’-TCGCTGCTGGCAGTTCTTGAGA-3’</td>
<td>5’-CGAACATGTTGGGTTGAGA-3’</td>
<td>NM_030679</td>
<td></td>
</tr>
<tr>
<td>Target candidates:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adam12</td>
<td>5’-CAGAGCATCACCAGCCAG-3’</td>
<td>5’-CAGGCTGAGATGCTGAGTC-3’</td>
<td>NM_007400</td>
<td></td>
</tr>
<tr>
<td>Calpastatin</td>
<td>5’-CCTTCAGCTGCTGAGAGAC-3’</td>
<td>5’-GCTGGTGCTGAGATGCTTCTC-3’</td>
<td>NM_009817</td>
<td></td>
</tr>
<tr>
<td>Caveolin3</td>
<td>5’-CACAAGGCTCGTATCGCCCTC-3’</td>
<td>5’-TCCGATGCTGCTTCTGGCTCA-3’</td>
<td>NM_017617</td>
<td></td>
</tr>
<tr>
<td>Ccna2</td>
<td>5’-CTTGCTGCTGAGCAGCTGAA-3’</td>
<td>5’-CAAACTCTGCTCTCCCAAAAACA-3’</td>
<td>NM_009828</td>
<td></td>
</tr>
<tr>
<td>Cdhl5</td>
<td>5’-TGGACATGCGCAACTCTGCTAC-3’</td>
<td>5’-GATGAGAGCTGCTGCAGGGAG-3’</td>
<td>NM_007662</td>
<td></td>
</tr>
<tr>
<td>Ctsb</td>
<td>5’-AAGCTGCTGTGGGACACTGCTCTG-3’</td>
<td>5’-GATCTATGCTCTCCCGAGGCAGC-3’</td>
<td>NM_007798</td>
<td></td>
</tr>
<tr>
<td>Itga3</td>
<td>5’-CATCAACATGCGAGAAAGCCACC-3’</td>
<td>5’-CCAACCCAGCCTACTCTCA-3’</td>
<td>NM_013565</td>
<td></td>
</tr>
<tr>
<td>Gene</td>
<td>Forward Primer</td>
<td>Reverse Primer</td>
<td>Reference Number</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>----------------</td>
<td>----------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>Itga4</td>
<td>5'-ACCAGACCTGCGAACAGC-3'</td>
<td>5'-CCCCCAGCCACTGGTTA-3'</td>
<td>NM_010576</td>
<td></td>
</tr>
<tr>
<td>Itga5</td>
<td>5'-TACTCTGTGCGGTGAGGTGA-3'</td>
<td>5'-GCCATTAAGGACGGTGACAT-3'</td>
<td>NM_010577</td>
<td></td>
</tr>
<tr>
<td>Itga6</td>
<td>5'-GGTTGAGAGGCCATGAAAG-3'</td>
<td>5'-TTCTTTTGTTCATACACGGACGA-3'</td>
<td>NM_008397</td>
<td></td>
</tr>
<tr>
<td>Itga9</td>
<td>5'-TGATGCAAAGCTGCTCTTTA-3'</td>
<td>5'-GAAATGCCCATCTCCTCCT-3'</td>
<td>NM_133721</td>
<td></td>
</tr>
<tr>
<td>Itgb1</td>
<td>5'-ATGCAGGTTGCGGTTTGT-3'</td>
<td>5'-CATCCGTGGAACACACCA-3'</td>
<td>NM_010578</td>
<td></td>
</tr>
<tr>
<td>Myof</td>
<td>5'-CATTACTGGCTTCTAAGCCTG-3'</td>
<td>5'-AAATTTACTCCACCAGTCAC-3'</td>
<td>NM_001099634</td>
<td></td>
</tr>
<tr>
<td>p21</td>
<td>5'-TGGGGCCCAGAACATCCT-3'</td>
<td>5'-TGCGCTTGGAGTGAAGAAA-3'</td>
<td>NM_007669</td>
<td></td>
</tr>
<tr>
<td>p57</td>
<td>5'-CAGGAGGAATCAAGGAC-3'</td>
<td>5'-TGCGCTTGGCGAAGAAGT-3'</td>
<td>NM_09876</td>
<td></td>
</tr>
<tr>
<td>Ptger4</td>
<td>5'-TCCAGATAGTCTCTTACT-3'</td>
<td>5'-TAACTGGTTAATGAACACTCGCA-3'</td>
<td>NM_001136079</td>
<td></td>
</tr>
<tr>
<td>Rb1</td>
<td>5'-GCTGCAAATACAGAGCACAAG-3'</td>
<td>5'-CGGAGATATGCTAGGCTGACTTT-3'</td>
<td>NM_009029</td>
<td></td>
</tr>
<tr>
<td>v-Cam1</td>
<td>5'-TGATTGGGAGAGACAAGA-3'</td>
<td>5'-AACAACCAGATCCTCCAACCT-3'</td>
<td>NM_011693</td>
<td></td>
</tr>
<tr>
<td>Vcl</td>
<td>5'-GATAGCTCTGCTGACCTCTAA-3'</td>
<td>5'-TAGTGCCGTCGCCACTTGT-3'</td>
<td>NM_009502</td>
<td></td>
</tr>
</tbody>
</table>

Reference genes:

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
<th>Reference Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>β-actin</td>
<td>5'-CTAAGGCCACCGGTGAAGAAG-3'</td>
<td>5'-ACCAGAGGCATACAGGGACA-3'</td>
<td>X03672</td>
</tr>
<tr>
<td>Gapdh</td>
<td>5'-CGTGTTCTACCCCAATGT-3'</td>
<td>5'-TGTCATCATACCTTGGCAGGT-3'</td>
<td>NM_008084</td>
</tr>
</tbody>
</table>